BioCryst to Report Second Quarter 2020 Financial Results on August 6

Rhea-AI Summary

BioCryst Pharmaceuticals (BCRX) is set to release its second quarter 2020 financial results on August 6, 2020. The company will host a conference call and webcast at 8:30 a.m. ET to discuss these results and provide a corporate update. Interested parties can access the call by dialing specific numbers for domestic and international callers and using the designated conference ID. BioCryst focuses on developing oral small-molecule medicines for rare diseases, with ongoing programs for treatments addressing hereditary angioedema, COVID-19, and other serious conditions.

RESEARCH TRIANGLE PARK, N.C., July 23, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2020 financial results on Thursday, August 6, 2020.

BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing 877-303-8027 for domestic callers and 760-536-5165 for international callers and using conference ID # 5142479. A live webcast of the call and any slides will be available online at the investors section of the company website at www.biocryst.com. A telephone replay of the call will be available by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference ID # 5142479.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. BioCryst has several ongoing development programs including berotralstat (BCX7353), an oral treatment for hereditary angioedema, BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, galidesivir, a potential treatment for COVID-19, Marburg virus disease and Yellow Fever, and BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva. RAPIVAB^® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst's first approved product and has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan, Korea and the European Union. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the Company's website at www.BioCryst.com.

BCRXW

Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

FAQ

When will BioCryst Pharmaceuticals report its second quarter 2020 financial results?

BioCryst Pharmaceuticals will report its second quarter 2020 financial results on August 6, 2020.

What time is the conference call for BioCryst Pharmaceuticals' Q2 2020 results?

The conference call for BioCryst Pharmaceuticals' Q2 2020 results is scheduled for 8:30 a.m. ET on August 6, 2020.

How can I access the BioCryst Pharmaceuticals conference call?

You can access the BioCryst Pharmaceuticals conference call by dialing 877-303-8027 for domestic callers or 760-536-5165 for international callers, using conference ID # 5142479.

What are the main products being developed by BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals is developing treatments for rare diseases, including berotralstat for hereditary angioedema and BCX9930 for complement-mediated diseases.